Shanghai RAAS Blood Products Co Ltd Class A (002252) — Financial Flexibility Index
Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Financial Flexibility Index of -0.13x as of December 2025. Free cash flow of CN¥-672.37 Million (operating CF CN¥-843.75 Million minus capex CN¥171.38 Million) represents 0% of total liabilities (CN¥5.33 Billion). Check Shanghai RAAS Blood Products Co Ltd Clas (002252) strategic investment index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Shanghai RAAS Blood Products Co Ltd Class A Financial Flexibility Index (2005–2025)
Historical Financial Flexibility Index trend for Shanghai RAAS Blood Products Co Ltd Class A across 21 annual periods. See 002252 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
Year-by-year free cash flow to debt coverage for Shanghai RAAS Blood Products Co Ltd Class A. For the full company profile including market capitalisation, see 002252 market cap.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.05x | CN¥274.12 Million | CN¥-104.89 Million | CN¥5.34 Billion | ▲ +215.9% |
| 2024 | -0.04x | CN¥-74.91 Million | CN¥-482.06 Million | CN¥1.69 Billion | ▼ -103.7% |
| 2023 | 1.20x | CN¥2.73 Billion | CN¥2.28 Billion | CN¥2.28 Billion | ▲ +0.9% |
| 2022 | 1.19x | CN¥1.95 Billion | CN¥1.73 Billion | CN¥1.64 Billion | ▲ +5.5% |
| 2021 | 1.12x | CN¥1.50 Billion | CN¥1.29 Billion | CN¥1.33 Billion | ▼ -71.2% |
| 2020 | 3.91x | CN¥1.42 Billion | CN¥1.17 Billion | CN¥363.74 Million | ▲ +37.6% |
| 2019 | 2.84x | CN¥1.03 Billion | CN¥872.69 Million | CN¥361.95 Million | ▲ +236.1% |
| 2018 | 0.84x | CN¥419.44 Million | CN¥262.50 Million | CN¥496.56 Million | ▲ +291.1% |
| 2017 | 0.22x | CN¥426.60 Million | CN¥268.76 Million | CN¥1.98 Billion | ▼ -58.9% |
| 2016 | 0.53x | CN¥785.71 Million | CN¥638.22 Million | CN¥1.50 Billion | ▼ -51.2% |
| 2015 | 1.08x | CN¥907.81 Million | CN¥762.42 Million | CN¥843.64 Million | ▲ +53.0% |
| 2014 | 0.70x | CN¥531.02 Million | CN¥465.96 Million | CN¥755.16 Million | ▲ +741.2% |
| 2013 | 0.08x | CN¥39.57 Million | CN¥-90.11 Million | CN¥473.37 Million | ▼ -96.2% |
| 2012 | 2.19x | CN¥413.16 Million | CN¥263.46 Million | CN¥188.79 Million | ▼ -49.3% |
| 2011 | 4.31x | CN¥354.82 Million | CN¥178.03 Million | CN¥82.26 Million | ▲ +47.7% |
| 2010 | 2.92x | CN¥289.42 Million | CN¥200.21 Million | CN¥99.12 Million | ▲ +2.1% |
| 2009 | 2.86x | CN¥177.01 Million | CN¥116.01 Million | CN¥61.88 Million | ▲ +59.7% |
| 2008 | 1.79x | CN¥136.87 Million | CN¥107.64 Million | CN¥76.42 Million | ▲ +22.2% |
| 2007 | 1.47x | CN¥200.17 Million | CN¥175.71 Million | CN¥136.53 Million | ▲ +276.0% |
| 2006 | 0.39x | CN¥65.67 Million | CN¥53.58 Million | CN¥168.39 Million | ▼ -47.5% |
| 2005 | 0.74x | CN¥75.71 Million | CN¥54.02 Million | CN¥101.93 Million | — |